Identifying genetic markers for radiation therapy response in breast cancer
Molecular Biomarkers of Response to Radiation Therapy in Breast Cancer
Institute of Oncology Ljubljana · NCT06648148
This study is trying to find genetic clues that can help predict how well breast cancer patients with ductal carcinoma in situ will respond to radiation therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Institute of Oncology Ljubljana (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Ljubljana) |
| Trial ID | NCT06648148 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify genetic and molecular biomarkers that predict how breast cancer patients respond to radiation therapy. It involves a monocentric approach at the Institute of Oncology Ljubljana, focusing on patients with ductal carcinoma in situ (DCIS) who are receiving adjuvant radiotherapy without systemic therapy. The study will assess adverse events related to radiation treatment over a five-year follow-up period and will analyze blood samples for biomarkers before, after, and during follow-up. Informed consent will be obtained from all participants, and the study has received ethical approval.
Who should consider this trial
Good fit: Ideal candidates for this study are breast cancer patients diagnosed with ductal carcinoma in situ (DCIS) who are indicated for adjuvant radiation therapy.
Not a fit: Patients undergoing systemic oncological therapy or those not indicated for adjuvant radiation therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective radiation treatment plans for breast cancer patients.
How similar studies have performed: While there have been studies exploring biomarkers in cancer treatment, this specific approach focusing on radiation therapy response in DCIS is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast cancer patients with DCIS with an indication for adjuvant radiation therapy Exclusion Criteria: * Any specific systemic oncological therapy
Where this trial is running
Ljubljana
- Institute of Oncology Ljubljana — Ljubljana, Slovenia (RECRUITING)
Study contacts
- Principal investigator: Tanja Marinko, MD, PhD — Institute of Oncology Ljubljana
- Study coordinator: Tanja Marinko, MD, PhD
- Email: tmarinko@onko-i.si
- Phone: 0038615879505
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer, Radiotherapy Side Effect